MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
June 14, 2023 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
May 30, 2023 07:00 ET
|
MediWound Ltd.
On track to initiate EscharEx® Phase III study in fourth quarter 2023NexoBrid® U.S. launch expected in early third quarter 2023Cash of over $57 million; Operating cash runway through profitability ...
MediWound to Report First Quarter 2023 Financial Results
May 12, 2023 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will...
MediWound Announces an Additional $10 Million Award from BARDA
May 09, 2023 07:30 ET
|
MediWound Ltd.
YAVNE, Israel, May 09, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
April 26, 2023 08:00 ET
|
MediWound Ltd.
Data to be highlighted in oral and poster presentations YAVNE, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on...
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
March 16, 2023 07:10 ET
|
MediWound Ltd.
2022 total revenues of $26.5 million FDA approval of NexoBrid® in December 2022; U.S. commercial availability expected in the second quarter of 2023 EscharEx® Phase III protocol design is under...
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
March 16, 2023 07:00 ET
|
MediWound Ltd.
YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue...
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
March 06, 2023 07:00 ET
|
MediWound Ltd.
Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development Appoints Alicia Torrenova, as Vice President of European Operations Both bring extensive leadership...
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
March 02, 2023 08:47 ET
|
MediWound Ltd.
YAVNE, Israel, March 02, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair...
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
February 23, 2023 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...